Related Experiment Video
Updated: May 14, 2026

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
Published on: June 23, 2023
α-Synuclein and mitochondrial dysfunction in Parkinson's disease
Stephen Mullin1, Anthony Schapira
1Department of Clinical Neurosciences, UCL, Institute of Neurology, Royal Free Campus, Pond Street, London NW3 2QG, UK. s.mullin@nhs.net
Abstract:
α-Synuclein (SNCA) is a substantive component of Lewy bodies, the pathological hallmark of Parkinson's disease (PD). The discovery and subsequent derivation of its role in PD has led to a suprising but fruitful convergence of the fields of biochemistry and molecular genetics. In particular, the manipulation of the cell lines of a number of forms of familial PD has implicated SNCA in distinct and diverse biochemical pathways related to its pathogenesis. This current and rapidly evolving concept indicates PD is a disease in which interacting pathways of oxidative stress, mitochondrial dysfunction and impaired regulation of protein turnover interact to cause dopaminergic cell dysfunction and death. SNCA has a central role in these processes and manipulation of its expression, degradation and aggregation appear to be promising neuroprotective therapeutic targets.
Related Concept Videos
Parkinson Disease ll: Pathophysiology
Parkinson Disease l: Introduction
Parkinson's Disease: Overview
Alterations in Muscle Tone lll
Neural Regulation
ATP Synthase: Mechanism

